Phielix et al.: Hepatic Fat Content and Adipokines

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Thiazoledinediones decrease blood glucose by their insulin-sensitizing properties. Here the investigators examined whether pioglitazone (PIO) improves insulin sensitivity independently of glycemic control and whether adipokines or non-esterfied fatty acids (NEFA) serve as mediators.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: German Diabetes Center
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• well controlled patients with type 2 diabetes (Hb1Ac < 8%)

• no insulin therapy

• no co-morbidities

• stable medication use for the last 6 months

• stable body weight the last 6 months

• no diet in the last 6 months

Exclusion Criteria:

• Hb1Ac > 8%

• insulin therapy

• diabetes-related co-morbidities, like cardiovascular disease, neuropathology

• unstable medication use

• unstable body weight in the last 6 months (> 5 kg)

• following a diet in the last 6 months